Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 16.11% and -0.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Surpasses Q1 Earnings Estimates

Shares of DaVita (NYSE:DVA) moved lower in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 14.21% year over year to $2.09, which beat the estimate of $1.80.

Recap: DaVita Q1 Earnings

DENVER, April 29, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2021. For the quarter, diluted earnings per share from continuing operations was $2.09, an increase of 15.5% from the prior year diluted earnings per share from continuing operations and an increase of 14.2% from the prior year adjusted diluted earnings per share from continuing operations.

DaVita Inc. 1st Quarter 2021 Results

DENVER, April 27, 2021 /PRNewswire/ -- DaVita Inc. today announced its 2025 Environmental, Social and Governance (ESG) goals and released its new ESG reports, bolstering its commitment to corporate citizenship and helping create healthy communities. DaVita's ESG program builds upon existing efforts to transform care, fight climate change and create a diverse community where everyone feels they belong.

DaVita Solidifies Commitment to ESG, Sets 2025 Goals

DENVER, April 22, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, April 29, 2021, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 1st Quarter 2021 Investor Conference Call

EAGAN, Minn., April 12, 2021 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced the launch of an innovative new program with VillageHealth − a DaVita integrated kidney care program − that addresses the holistic health needs of certain eligible members with chronic kidney disease (CKD) or end stage kidney disease (ESKD).

Blue Cross and Blue Shield of Minnesota Launches Program with DaVita's VillageHealth to Improve Care for Members with Kidney Disease

Chemed

Emergent BioSolutions

ICON

Select Medical Holdings

The following health care companies have grown their earnings per share over a five-year period. According to the GuruFocus discounted cash flow calculator as of March 31, all of them also trade with a margin of safety.

5 Health Care Stocks Boosting Earnings

DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.

DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care

DENVER, March 29, 2021 /PRNewswire/ -- DaVita today published its inaugural Diversity & Belonging (D&B) report, which discloses its diversity metrics and roadmap for delivering its vision of cultivating "a diverse Village where everyone belongs." "Fostering an environment that is rich in diversity and where we all belong is imperative to our culture and how we connect with each other and our patients every day," said Javier Rodriguez, CEO for DaVita Inc. "Publishing this report not only underscores the seriousness with which we take diversity and belonging, but it also holds us accountable for making continued and intentional forward progress.

DaVita Shares Strategy for Achieving a Diverse Community Where Everyone Belongs

Since dialysis is a stable business, Davita Inc (NYSE: DVA) remained resilient during the pandemic. However, now with acceleration in volumes is poised to begin, the company “is not as levered to the expected utilization rebound as peers,” according to BofA Securities.

BofA Downgrades DaVita On Low Exposure to Volume Rebound

Snowflake

Zoom Video

Guess?

Knight-Swift Transportation Holdings

With the trading day about halfway over, the broad markets were cautiously positive.

CSX, Guess, Snowflake, Zoom Video and More Friday Afternoon Analyst Calls

DENVER, March 25, 2021 /PRNewswire/ -- Today, the Biden administration announced a new partnership with dialysis providers to provide COVID-19 vaccinations to people receiving dialysis and health care personnel in outpatient dialysis centers. DaVita Kidney Care will receive a portion of this allocation and will work with other providers to make vaccines available in dialysis centers across the country.

DaVita Statement on Government's Nationwide Program to Vaccinate Dialysis Patients

WALTHAM, Mass. and DENVER, March 23, 2021 /PRNewswire/ --  Fresenius Medical Care North America (FMCNA) and DaVita Kidney Care today announced an expanded agreement to provide home dialysis technology—including NxStage home hemodialysis (HHD) machines, dialysis supplies, and a connected health platform—to DaVita patients across the United States.

DaVita Kidney Care Expands Use of NxStage Home Hemodialysis Machines from Fresenius Medical Care

SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2021 / NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million. DaVita Venture Group led the investment round, with participation from DigitalDx Ventures and other previous investors.

NephroSant Announces $16 Million Series A, Led by DaVita Venture Group

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

DaVita HealthCare (DVA) Down 4.3% Since Last Earnings Report: Can It Rebound?

DENVER, March 9, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced today that the company will participate in the 2021 Barclays Global Healthcare Conference. Joel Ackerman, DaVita's Chief Financial Officer, will answer questions in a virtual fireside chat on Wednesday, March 10,...

DaVita Inc. to Participate in the 2021 Barclays Global Healthcare Conference

Best Buy

DXC Technology

Twenty-First Century Fox

Lumen Technologies

Altria

Pfizer

Sprouts Farmers Markets

Verizon

What are some examples of "cheap stocks" in today's still-strong stock market? These 9 may be great value plays to consider.

9 Cheap Stocks That Look Like a Bargain

DENVER, Feb. 24, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030 (the "notes"). The principal amount of...

DaVita Inc. Announces Upsize and Pricing of Add-On Offering of $1 Billion Senior Notes

Apple

Amazon

Liberty Global Ltd

T-Mobile US

Warren Buffett stocks may have more competition. But analysts agree a few big winners are good bets for the future — including some in the S&P 500.

6 Top Warren Buffett Stocks Still Have Big Upside, Analysts Agree

DENVER, Feb. 24, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today that it has commenced a private add-on offering of $750 million aggregate principal amount of its 4.625% senior notes due June 1, 2030 (the "notes"), subject to market and other conditions. The notes...

DaVita Inc. Announces Add-On Offering of $750 Million Senior Notes

Allegiant Travel Company

Goldman Sachs

Spirit Airlines

Francis Chou (Trades, Portfolio), manager of Chou Associates Management, disclosed last week that his firm's top four sells during the fourth quarter of 2020 included the closure of its position in Spirit Airlines Inc. (NYSE:SAVE) and Allegiant Travel Co. (NASDAQ:ALGT) and a reduction in its holding of DaVita Inc. (NYSE:DVA) and Goldman Sachs Group Inc. (NYSE:GS).

Francis Chou's Top 4 Sells of the 4th Quarter

Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.

Here's Why You Should Retain DaVita (DVA) in Your Portfolio Now

DaVita's (DVA) bottomline in Q4 declines year over year.

DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates

DaVita, Inc. (DVA) CEO Javier Rodriguez on Q4 2020 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -9.73% and -1.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

News for DaVita Stock (DVA)